Pharmaceutical composition for preventing and treating chronic obstructive lung disease containing, as active ingredient, Magnoliae flos extract, fraction, or active fraction thereof
申请人:KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
公开号:US10376553B2
公开(公告)日:2019-08-13
A pharmaceutical composition includes any of an extract of Magnoliae flos, a fraction or an active fraction obtained by fractionation thereof with an organic solvent, and a compound separated therefrom as an active ingredient. The extract of Magnoliae flos, the fraction or the active fraction obtained by fractionation thereof with an organic solvent, or the compound separated therefrom inhibits the expression of MUC5AC induced by TNF-α and the promoter activity in human lung cancer mucosal cells (H292), reduces the number of inflammatory cells in the bronchoalveolar lavage fluid of the chronic obstructive pulmonary disease mouse model, inhibits the production of reactive oxygen species, and reduces the cytokines; and therefore are effective in preventing or treating chronic obstructive pulmonary disease.
一种药物组合物包括作为活性成分的厚朴提取物、用有机溶剂分馏得到的馏分或活性馏分以及从中分离出的化合物中的任意一种。厚朴提取物、用有机溶剂分馏得到的馏分或活性馏分或从中分离得到的化合物可抑制 TNF-α 诱导的 MUC5AC 的表达和人肺癌粘膜细胞(H292)的启动子活性,减少慢性阻塞性肺病小鼠模型支气管肺泡灌洗液中炎性细胞的数量,抑制活性氧的产生,减少细胞因子;因此可有效预防或治疗慢性阻塞性肺病。